Jaguar Health, Inc. announced that stockholders approved five proposals at its 2026 Annual Meeting, which was adjourned until June 8, 2026. The company focuses on developing novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal disease states. The approval of all proposals marks a key milestone in the company's corporate governance and strategic direction.

The proposals, detailed in the company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (SEC) on April 30, 2026, cover various corporate matters. Stockholders can access the proxy statement and other SEC filings for free at the SEC's website or Jaguar's corporate website. The meeting's adjournment to June 8, 2026, allowed for finalizing voting results.

Jaguar Health's family of companies includes Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., which focus on developing and commercializing crofelemer powder for rare gastrointestinal disorders. Another subsidiary, Magdalena Biosciences, a joint venture with Filament Health Corp., is developing plant-derived prescription medicines for mental health indications.

The company's management, including founder, president & CEO Lisa Conte, is set to present virtually at the Emerging Growth Conference on June 10, 2026. The presentation will be available online, with a replay accessible on EmergingGrowth.com and the Emerging Growth YouTube Channel. This event underscores Jaguar's commitment to engaging with investors and stakeholders.

Jaguar Health's forward-looking statements emphasize its expectations for future growth and development, though these are subject to risks and uncertainties. The company does not plan to publicly update these statements unless required by law. For more information, stakeholders can visit Jaguar Health's official website or those of its subsidiaries.